Canadians continue to pay almost twice as much as Americans for generic prescription drugs, says think tank

14 October 2010

Canadians are paying almost twice as much for generic prescription drugs as Americans because government drug plans distort retail prices and prevent manufacturer discounts from being passed on to consumers, concludes a new study released yesterday by the Fraser Institute, Canada’s leading public policy think-tank.

Canadian prices on 64 generic prescription drugs available in both Canada and the United States were 90 per cent higher on average than American prices for the same drugs, according to Canada’s Drug Price Paradox 2010.

The study compares Canadian and American retail prices for an identical group of the most commonly prescribed generic drug products sold in Canada in 2008 (the most recent year for which data are available). Previous editions of the study found that generic prescription drug prices in Canada in 2007 were an average of 112% higher than those in the USA and 115% higher in 2006.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Generics